Drug resistance and off-target toxicity
are two of the greatest
challenges to chemotherapeutic melanoma treatments. Nitric oxide (NO)
represents an attractive alternative to conventional therapeutics
due to its numerous anticancer properties and low probability of engendering
resistance. As NO is highly reactive, macromolecular NO donors are
needed for the controlled and targeted delivery of NO for therapeutic
applications. Herein, mesoporous silica nanoparticles (MSNs) coated
with hyaluronic acid (HA) were developed as a NO delivery system to
facilitate controlled delivery to cancer cells through both passive
and active targeting via the enhanced permeation and retention effect
and directed binding of HA with CD44 receptors, respectively. The
aminosilane modification, HA concentration, and HA molecular weight
were systematically evaluated to facilitate the MSN coating and NO
loading. The hydrodynamic diameter and dispersity of the nanoparticles
increased after HA coating due to the hydrophilic nature of HA, with
greater increases observed at higher HA molecular weight. Lower starting
concentrations of HA and aminosilanes with longer alkyl chains favored
more efficient HA coating. Faster NO-release kinetics and lower NO
payloads were observed for the HA-coated MSNs relative to uncoated
MSNs. However, the localized delivery of NO to cancer cells through
the active targeting conferred by HA increased levels of oxidative
stress and induced mitochondria-mediated apoptosis in melanoma cells.
Cytotoxicity
was also evaluated against human dermal fibroblasts, with the use
of 6 kDa HA-coated MSNs resulting in the greatest therapeutic indices.
Enhanced internalization of HA-coated nanoparticles into melanoma
cells versus uncoated nanoparticles was visualized with confocal microscopy
and quantified by fluorescence spectroscopy. In total, HA-coated MSNs
represent a promising NO delivery system for potential use as a chemotherapeutic
for skin melanomas.